alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer.
Authors: Rubin Mark A; Zhou Ming; Dhanasekaran Saravana M; Varambally Sooryanarayana; Barrette Terrence R; Sanda Martin G; Pienta Kenneth J; Ghosh Debashis; Chinnaiyan Arul M;
Journal:JAMA
PubMed ID:11926890
'Edited due to space constraints: CONTEXT: Molecular profiling of prostate cancer has led to the identification of candidate biomarkers and regulatory genes. Discoveries from these genome-scale approaches may have applicability in the analysis of diagnostic prostate specimens. OBJECTIVES: To determine the expression and clinical utility of alpha-methylacyl coenzyme A racemase ... More
Molecular cross-talk between the TRAIL and interferon signaling pathways.
Authors: Kumar-Sinha Chandan; Varambally Sooryanarayana; Sreekumar Arun; Chinnaiyan Arul M;
Journal:J Biol Chem
PubMed ID:11677236
TRAIL/APO-2L induces apoptosis in a variety of transformed cells and has potential as an anti-cancer therapeutic. The physiologic role of TRAIL is presumably more complex than merely activating caspase-mediated cell death. To shed light into TRAIL-mediated signaling, we used DNA microarrays to profile gene expression mediated by TRAIL in breast ... More
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
Authors: Higashi Mitchell K; Veenstra David L; Kondo L Midori; Wittkowsky Ann K; Srinouanprachanh Sengkeo L; Farin Fred M; Rettie Allan E;
Journal:JAMA
PubMed ID:11926893
Edited for space constraints: Warfarin is a commonly used anticoagulant that requires careful clinical management to balance the risks of overanticoagulation and bleeding with those of underanticoagulation and clotting. The principal enzyme involved in warfarin metabolism is CYP2C9, and 2 relatively common variant forms with reduced activity have been identified, ... More